BSEBoard Meeting2d ago · 15 Oct 2026, 08:13 pm
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting scheduled to be held on October 20, 2026, inter alia to consider and approve enabling resolution for raising of funds
Orchid Pharma Ltd · 524372
✦ AI SummaryFundraise
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 to consider and approve enabling resolution for raising of funds.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On October 20, 2026.
Attachments (1)
📄pdf
Download →
444e15e7-2db9-4e67-ac26-20f1cf710ca3.pdf
View document text
October 15, 2026
National Stock Exchange of India Limited, BSE Limited
Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers,
Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai- 400001
Symbol: ORCHPHARMA Scrip Code: 524372
Ref: Regulation 29 of Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended
Sub: Prior Intimation of Board Meeting scheduled to be held on October 20,
2026
Dear Sir/Madam,
With reference to captioned subject and in accordance with Regulation 29 of Securities and Exchange
Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended,
this is to intimate that the meeting of Board of Directors of Orchid Pharma Limited (“the Company”)
is scheduled to be held on Tuesday, October 20, 2026, to consider and evaluate various options for
raising funds by way of issue of equity shares or any other eligible securities or instruments,
including fully or partly convertible debentures, or through a composite issue of non-convertible
debentures and warrants entitling the warrant holder(s) to apply for equity shares or other eligible
securities, by way of qualified institutions placement/ preferential issue/ private placement, public
issue of equity shares and/or debt securities or through any other permissible mode, or any
combination thereof, as may be considered appropriate, subject to such statutory and regulatory
approvals as may be required, including the approval of the members of the Company, wherever
applicable, and such other approvals, permissions and consents as may be necessary
You are requested to take the above intimation on record
Thanking You,
For Orchid Pharma Limited
Kapil Dayya
Company Secretary & compliance officer
Mem No.: F10698